<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031963</url>
  </required_header>
  <id_info>
    <org_study_id>R01CA128641</org_study_id>
    <nct_id>NCT04031963</nct_id>
  </id_info>
  <brief_title>Novel Biophotonics Methodology for Colon Cancer Screening</brief_title>
  <acronym>BRP</acronym>
  <official_title>Novel Biophotonics Methodology for Colon Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NorthShore University HealthSystem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proposal to establish a Bioengineering Research Partnership (BRP). The major&#xD;
      objective of the BRP is to refine and provide comprehensive, definitive multi-center&#xD;
      validation of these novel methodologies for colorectal cancer (CRC) screening, thus providing&#xD;
      a quantum leap in population screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Significance highlights the impracticality to provide total colonic evaluation&#xD;
      for the entire population. Risk-stratification via exploitation of the &quot;field effect&quot; is an&#xD;
      attractive approach. However, all existing methodologies (e.g FOBT, fecal DNA, flexible&#xD;
      sigmoidoscopy) are clearly suboptimal underscoring the need for novel tools for identifying&#xD;
      the field effect.&#xD;
&#xD;
      1) We have developed ELF/LEBS for depth-selective (from ~30 to hundreds of microns)&#xD;
      spectroscopic assessment of living tissue. 2) We tested these novel techniques in two animal&#xD;
      models of CRC (the AOM-treated rat and MIN-mouse) and in human subjects (n=190). We&#xD;
      demonstrated that ELF/LEBS has the potential to detect precancerous changes in the colon at a&#xD;
      time point that precedes the formation of adenomas and other histological/molecular markers&#xD;
      of CRC. 3) We demonstrated that rectal ELF/LEBS can detect field effect alterations in&#xD;
      histologically normal rectal tissue changes due to the presence of adenomas anywhere in the&#xD;
      colon. In our pilot studies, the diagnostic accuracy of rectal ELF/LEBS far exceeded any&#xD;
      other currently known markers of CRC. Therefore, assaying ELF/LEBS in the rectum has the&#xD;
      potential to provide accurate risk-stratification for colon carcinogenesis without the need&#xD;
      for bowel preparation and colonoscopy. 4) We have developed prototypes of ELF and LEBS&#xD;
      fiber-optics probes for in vivo use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Early cancer changes in the colon</measure>
    <time_frame>Visit 1, screening colonoscopy</time_frame>
    <description>ELF/LEBS probe used to obtain spectroscopy readings from rectal tissue</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">857</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <description>Those with colon cancer and with adenomatous polyp and those without a previously mentioned condition.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients going under colonoscopy or sigmoidoscopy procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is 18 years old or older and is having a colonoscopy procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent usage of anticoagulation or blood thinner medication within the last 7 days&#xD;
             that would preclude Hx of Inflammatory Bowel Disease/Colitis/Chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hemant Roy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NorthShore Univeristy HealthSystems</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Novel Biophotonic Methodology for Colon Cancer Screening.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

